Giant Bio Launches First Class III Medical Device 'KeLijin Xinsheng' at Mevolos Conference

On April 10, 2026, the 23rd MedVerse Research Conference, themed “Navigating Cycles · Partnering with AI,” grandly opened at the Hangzhou International Expo Center. As a global leader in recombinant collagen, Giant Biogene showcased its brand Collgene at this prestigious industry event. Notably, Giant Biogene’s first product to receive a Class III medical device registration certificate—Recombinant Type I α1 Collagen Lyophilized Fiber (brand name: Collgene Xinsheng)—made its public debut, marking Giant Biogene’s formal entry into the expansive market for skin rejuvenation.

During the thematic sharing session of the conference, Professor Duan Zhiguang, Chief Technology Officer of Giant Biogene, provided an in-depth interpretation of the core technical value of recombinant Type I collagen. He revealed that Giant Biogene successfully isolated a long sequence consisting of 753 amino acids from the α1 chain of Type I collagen. “The consistency and integrity of this sequence with the natural human sequence have demonstrated higher safety through both theoretical analysis and practical biological validations.” Professor Duan stated that, leveraging its proprietary synthetic biology technology, Giant Biogene has achieved precise design, efficient R&D, and large-scale production of multiple types of recombinant collagen, establishing globally leading industrialization capabilities for recombinant collagen.

He further pointed out that the core competitiveness of “Collgene Xinsheng” lies in the distinctiveness of its recombinant Type I collagen components and the high integrity of their sequences. Currently, in the domestic market for recombinant collagen injectable products, Giant Biogene is the only company with a portfolio featuring “recombinant Type I collagen” injectables. “This reflects a profound response to user needs—aiming solely to provide more diverse and reassuring choices.” Meanwhile, Professor Duan Zhiguang emphasized that the company adheres to a “clinical-need-driven R&D” approach, maintaining long-term, deep co-creation mechanisms with dermatology and plastic surgery experts at top-tier tertiary hospitals in China. By proactively identifying pain points and challenges encountered in clinical practice, the company has established a closed-loop system of “R&D–clinical application–feedback–iteration,” ensuring that its products meet both the practical requirements of clinical procedures and consumers’ aesthetic improvement needs.

At the exhibition, Collgene showcased its full product portfolio, ranging from its comprehensive line of functional skincare products for the mass consumer market, to its Class II medical devices deeply entrenched in professional medical aesthetics clinics, and further to its newly launched Class III medical device, “Collgene Xinsheng.” This milestone establishes Collgene as a high-barrier consumer brand—one of the few in China and globally—to simultaneously cover Class II medical devices, Class III medical devices, and skincare categories, thereby integrating the three core beauty scenarios: medical aesthetics, lifestyle beauty, and home skincare.

The synergistic combination of Class III product certifications creates a powerful complementarity, not only establishing a dual moat of regulatory qualifications and technology that is difficult for competitors to replicate for Collgene, but also feeding back into the consumer-facing home skincare segment with medical-grade scientific research standards. This deeply embeds the brand perception of “clinical-grade safety, research-grade efficacy, and all-scenario adaptability” into consumers’ minds.

As the first enterprise in China to achieve large-scale production of recombinant collagen and apply it in the field of medical devices, Giant Biogene has launched “Collgene Core Life,” which features extremely high R&D barriers, clinical validation standards, and regulatory requirements. This signifies that the company has established a complete technological pathway from “consumer-grade skincare” to “implantable-grade biomaterials,” thereby forming unique core advantages in the fiercely competitive recombinant collagen sector.

Meanwhile, leveraging its comprehensive product portfolio across all categories and scenarios, Collgene will continue to deepen strategic collaborations with professional channels, thereby enhancing its influence and voice within the upstream and downstream segments of the medical aesthetics industry chain. This represents not only a significant leap in brand value but also a vivid microcosm of China’s recombinant collagen industry transitioning from “raw material leadership” to “product and solution leadership.”

The implementation of technological innovations and the expansion of product portfolios are invariably underpinned by a company’s core industrial capabilities and market systems. As an industry leader with over two decades of deep expertise in recombinant collagen, Giant Biogene has transcended the traditional industry models focused solely on raw material supply or product manufacturing. By establishing a closed-loop, full-industry-chain ecosystem that integrates upstream independent R&D of raw materials, midstream product registration and commercialization, and downstream omni-channel distribution, the company has laid a solid foundation for scaling its core technologies from laboratory research to broad market application.

In terms of market layout, Giant Biogene adopts a dual-track sales strategy of “medical institutions + mass consumers,” building a three-dimensional terminal network covering the whole country. Official data shows that by the end of 2025, its core products have entered about 1,700 public hospitals, about 3,000 private hospitals and clinics, and more than 130,000 chain pharmacy stores across China. This layout not only builds a core bridge for the company to connect clinical and consumer markets, but also provides a solid market foundation and channel advantages for the debut of “Collgene Core Life.”

From an industrial perspective, Giant Biogene has built not just a single product line, but a complete, end-to-end ecosystem for “China-originated biomaterials,” spanning from foundational laboratory research and pilot-scale scale-up to regulatory clinical trials, large-scale manufacturing, and final market deployment. It is precisely this systematic capability that has enabled Giant Biogene to bridge the “last mile” from “technological leadership” to “market leadership.” This demonstrates that Chinese enterprises are not only capable of developing world-class original technologies, but can also leverage integrated industrial capabilities to ensure these technologies deliver tangible benefits to both clinical practice and consumers.

From daily skincare with functional benefits to professional medical aesthetic injections, Giant Biogene has established a comprehensive health management solution covering all scenarios and full lifecycle stages. Looking toward a broader future, the application boundaries of recombinant collagen are expanding into cutting-edge fields such as tissue engineering and artificial organs, demonstrating limitless potential.

Today, the narrative of regenerative anti-aging centered on recombinant collagen is gradually breaking free from the constraints of overseas technological pathways, with Chinese brands authoring original chapters. Giant Biogene’s recent technological breakthrough and successful product commercialization have accelerated the restructuring of the global regenerative aesthetics landscape by high-end domestic medical aesthetics through independent innovation. This is no longer merely a single company’s breakthrough, but the rise of an entire industrial chain; it is not just the success of one product category, but a historic turning point for China’s biomanufacturing sector—from “technological catch-up” to “standard-setting.” As the global map of regenerative aesthetics is redrawn, China is transitioning from a participant to a leader—with Giant Biogene serving as a key architect of this historic leap.